Myeloid Mas drives pyruvate kinase M2-mediated Spi1 lactylation to fuel inflammatory senescence in MASLD
Lu-Don Zhao, Shujing Xu, Shikai Qiao, Zhe Wang, Shenglan Wang, Chun Liu, Shuo Zhang, Peng Wang, Xianghua Sun, Shanshan Li, Li Chen, Xiaokun Zhang, Chengxi Hu, Yongping Zhou, Lu Xia, Changqing Yang, Jing Li
Paper details
- Journal
- Signal Transduction and Targeted Therapy
- Published
- 2026.5.19
- Citations
- 0
- References
- 49
- Fields
- Medicine, Biology
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is driven by unresolved inflammation, yet precise mechanisms linking immune metabolism to disease progression remain elusive. Here, we identified myeloid-expressed Mas, a G protein-coupled receptor, as a critical metabolic checkpoint in MASLD. Mas expression is elevated in hepatic myeloid cells from patients and diet-induced mouse models. Myeloid-specific Mas1 deletion attenuated MASLD by restraining glycolytic reprogramming and inflammatory senescence. Single-cell RNA sequencing analyses revealed that this deletion specifically impaired the glycolytic flux and subsequent pathogenic differentiation of FN1⁺CCR2⁺ monocyte precursors. Mechanistically, Mas interacts with the glycolytic enzyme PKM2, enhancing lactate production that drives lactylation of the transcription factor Spi1 at lysine 208. Spi1-K208 lactylation promotes its nuclear localization and transcriptional activation of senescence-associated secretory phenotype (SASP) genes. Myeloid-specific Pkm2 ablation phenocopied the protective effect of Mas1 deletion, and PKM2 overexpression rescued the metabolic and transcriptional defects caused by Mas loss. Virtual screening identified theaflavin-3,3′-digallate (TFDG) as a Mas inhibitor that disrupts the Mas-PKM2 interaction. A macrophage membrane-coated nanoparticle (MM@NP-TFDG) delivered TFDG specifically to hepatic macrophages, suppressed the Mas-PKM2-Spi1 lactylation axis, and ameliorated MASLD pathology in vivo. Our findings define a novel Mas-PKM2-Spi1 lactylation axis that orchestrates glycolytic reprogramming, monocyte precursor differentiation, and macrophage-driven inflammation in MASLD, presenting a targeted nanotherapeutic strategy for its treatment.
Citation format
ZHAO, Lu-Don, et al. Myeloid mas drives pyruvate kinase m2-mediated spi1 lactylation to fuel inflammatory senescence in MASLD. Signal Transduction and Targeted Therapy, 2026, 11(1).